We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
P5.2
Phosphorus Research
Mostly mechanism / observational
21 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Phosphorus studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality randomised trials published 1981–2026 with a typical study size of 122 participants.
Based on 21 studies · 9 RCTs · 2,343 total participants
Confidence
High confidence
By outcome
Kidney & renal health
Mostly mechanism / observational7 studies
Therapeutic & clinical
Mostly mechanism / observational6 studies
Bone healthPhosphorus is a structural component of bone mineral (hydroxyapatite), but supplementation helps bone only when intake is genuinely deficient; most people get enough from food, and excess can disturb calcium balance · Only relevant in documented deficiency
Mostly mechanism / observational3 studies
Heart & blood pressure
Too few graded studies1 study
Longevity & aging
Too few graded studies1 study
Active research area
9 studies in the last 5 years
198120032026
1Review2017
In plain English: Rickets is a bone disease associated with abnormal serum calcium and phosphate levels.
Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM · Nature Reviews Disease Primers (2017)
Rickets is caused by nutritional deficiencies or genetic defects affecting vitamin D metabolism, FGF23, renal phosphate handling, or bone mineralization.
The clinical picture includes bowing deformities of the legs, short stature, and widening of joints, varying by age of onset and cause.
Oral phosphate supplementation is usually indicated for FGF23-independent phosphopenic rickets.
In plain English: In humans, 80% of the body phosphorus is present in the form of calcium phosphate crystals (apatite) that confer hardness to bone and teeth, and function as the major phosphorus reservoir.
Peacock M · Calcified Tissue International (2021)
Phosphorus is a key element in organic molecules involved in essential cellular functions: ATP energy transfer, DNA/RNA, cAMP signaling, and glycerophospholipid membrane integrity.
About 80% of body phosphorus resides in bone and teeth as calcium-phosphate apatite, serving as the major reservoir; the remainder is in soft tissue and extracellular fluid.
At physiological pH, inorganic phosphate exists as both H2PO4- and HPO4(2-) and acts as an extracellular-fluid buffer.
In plain English: Although phosphorus is an essential nutrient required for multiple physiological functions, recent research raises concerns that high phosphorus intake could have detrimental effects on health.
Chang AR, Anderson C · Annual Review of Nutrition (2017)
Phosphorus is abundant in the food supply of developed countries, occurring naturally in protein-rich foods and as an additive in processed foods.
High phosphorus intake can cause vascular and renal calcification, renal tubular injury, and premature death in multiple animal models.
Small human studies suggest high phosphorus intake may produce positive phosphorus balance and correlate with renal calcification and albuminuria.
In plain English: Recent findings show that increasing dietary phosphorus through inorganic phosphate additives has detrimental effects on bone and mineral metabolism in humans and animals.
Vorland CJ, Stremke ER, Moorthi RN, Hill Gallant KM · Current Osteoporosis Reports (2017)
The average phosphorus intake in the USA is well above the recommended dietary allowance.
Inorganic phosphate additives are absorbed at a high rate and account for a substantial, likely underestimated, portion of excessive intake.
Phosphate additives have negative effects on bone metabolism and present a prime opportunity to lower total phosphorus intake.
In plain English: FGF23 is an important hormonal regulator of phosphate homeostasis... it modulates phosphate reabsorption... in the renal proximal tubules.
Imel EA, Biggin A, Schindeler A, Munns CF · JBMR Plus (2019)
FGF23, with its co-receptor Klotho, regulates renal phosphate reabsorption and vitamin D hydroxylation.
X-linked hypophosphatemia (XLH), caused by PHEX mutations, is the most common FGF23-mediated hypophosphatemia.
FGF23-mediated hypophosphatemias cannot be cured with nutritional vitamin D and historically required oral phosphate plus active vitamin D analogs.
In plain English: These findings support the integration of personalized educational strategies as a key component in the comprehensive management of hyperphosphatemia in routine hemodialysis practice.
Arenas Jiménez MD, García de Polavieja MD, Escribano S, Audije-Gil J, Sánchez-Tocino ML, Henríquez-Palop F, Antón Pérez G, Yetman D, Pereira M, Molina P, Auxiliadora Bajo M, Jesús Lloret M, Quilis A, Fernández C, García Monteavaro C, María León L, Botella A, Ballart J, Durbá A, Furaz K, González Parra E, Handel M, Delgado Yagüe M, Antonio Herrero J, Dapena Bielva F, Grupo de trabajo Empower-PHOS. · Nefrologia (2026)
The intervention group achieved significant reductions in serum P at 3 months (from 6.1 to 5.4 mg/dl; p < .001) and at 12 months (from 6.2 to 5.2 mg/dl; p = .010), without changes in the number of pills or daily binder dose.
Improvements were observed in both adherent and non-adherent patients, with particularly notable reductions among the latter (from 6.4 ± 1.2 to 5.8 ± 1.2 mg/dl; p = .015).
Adherence according to SMAQ did not change significantly.
In plain English: A high-caloric diet or rapid refeeding in children/adolescents suffering from AN may be both safe and effective, with serial laboratory investigations and phosphate supplementation as needed.
Mosuka EM, Murugan A, Thakral A, Ngomo MC, Budhiraja S, St Victor R · Cureus (2023)
Systematic review of 20 full-text studies on high-caloric refeeding protocols in children and adolescents with anorexia nervosa, totaling 2,191 participants.
Hypophosphatemia — the biochemical hallmark of refeeding syndrome — was a central monitored outcome across the included studies.
A lower BMI at hospital admission was a better predictor of hypophosphatemia than total caloric intake.
In plain English: Potentially modifiable risk factors for osteoporosis are vitamin D deficiency... low calcium intake, low or excessive phosphorus intake, protein deficiency or a high-protein diet.
Tański W, Kosiorowska J, Szymańska-Chabowska A · European Review for Medical and Pharmacological Sciences (2021)
Osteoporosis affects over 200 million people worldwide and is defined by low bone mineral density (T-score ≤ -2.5).
Both low AND excessive phosphorus intake are listed among modifiable dietary risk factors for osteoporosis — underscoring that balance, not more, is what protects bone.
Other modifiable risks include vitamin D deficiency, low calcium intake, smoking, alcohol, and a sedentary lifestyle.
In plain English: We present recommendations for phosphate repletion in CRRT to prevent hypophosphatemia, and describe our experience using phosphate-containing CRRT solutions.
Heung M, Mueller BA · Seminars in Dialysis (2018)
Hypophosphatemia is a common, under-recognized complication of continuous renal replacement therapy (CRRT) in critically ill patients.
Continuous filtration removes phosphate, and without repletion patients readily become hypophosphatemic.
The review provides practical recommendations for phosphate repletion during CRRT.
In plain English: Postsurgical HypoPT remains a significant complication of thyroid surgery; however, its risk can be mitigated by careful preoperative assessment and surgical technique.
Ali DS et al. · Thyroid : official journal of the American Thyroid Association (2026)
Postsurgical HypoPT remains a significant complication of thyroid surgery; however, its risk can be mitigated by careful preoperative assessment and surgical technique.
While conventional therapy continues to be the mainstay of treatment, the advent of PTH replacement therapies offers promising alternatives for patients with refractory HypoPT.
In plain English: Highly bioavailable phosphorus additives disrupt mineral metabolism and contribute to broader metabolic dysfunction, supporting the need for updated dietary recommendations and further mechanistic and clinical investigation.
Gutiérrez OM · Current opinion in nephrology and hypertension (2026)
Published in Current opinion in nephrology and hypertension (2026)
In plain English: Despite the small sample size and brief intervention, these findings suggest that short-term dietary phosphorus restriction may influence bone formation and resorption markers in hemodialysis patients.
Peng YS, Sun WH, Wu HY, Chiu YL, Yang JY, Pai MF, Hsu SP, Lin WY, Chu FY, Tsai WC. · Scientific reports (2026)
The therapeutic diet significantly increased BAP levels after 7 days (median difference: + 0.8 μg/L, P = 0.02), but did not alter other markers.
In multivariate models, a 100 mg reduction in dietary phosphorus intake corresponded to a 0.9% increase in BAP, 2.8% in P1NP, and 1.7% in TRACP-5b.
Mixed-effects models assessed associations between dietary phosphorus intake and bone turnover markers.